H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

The impact of this deal on the stock market has been quite bullish, especially for AI-related companies and those involved in ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

Shares of vaccine makers moved higher early Monday following a CDC report that the U.S. was seeing a significant uptick in acute respiratory illness due to higher rates of seasonal influenza ...

The signs of a potential bird flu transmission have provided some respite to these vaccine-focused stocks, especially to those who made COVID-19 vaccines. Vaccine makers, especially Moderna and ...

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...